P2Y12受体抑制剂的药物遗传学
本文综述了氯吡格雷、普拉格雷和替格瑞洛三种口服P2Y12抑制剂的药物遗传学证据。氯吡格雷经CYP2C19激活,约30%个体携带CYP2C19无功能等位基因,导致活性代谢物暴露降低和血小板抑制减弱。CYP2C19基因型指导的PCI术后抗血小板治疗是临床药物遗传学实施的常见范例,专家共识和监管机构已提供整合遗传信息的指导。
要点
- 氯吡格雷是前药,主要经CYP2C19生物激活,约30%个体携带CYP2C19无功能等位基因。
- CYP2C19无功能等位基因携带者氯吡格雷活性代谢物暴露降低,血小板抑制减弱。
- PCI术后CYP2C19基因型指导抗血小板治疗是临床药物遗传学实施的常见范例。
核心结论
- 综合考虑临床和遗传因素可指导P2Y12抑制剂选择,以最佳平衡动脉血栓和出血风险。
研究设计与样本
- 本文为综述,回顾了氯吡格雷药物遗传学关联及基因型指导P2Y12抑制剂选择的证据。
主要发现
- 氯吡格雷经CYP2C19激活,约30%个体携带CYP2C19无功能等位基因,酶活性降低或缺失。
- 氯吡格雷治疗的CYP2C19无功能等位基因携带者活性代谢物暴露降低,血小板聚集抑制减弱。
- 普拉格雷和替格瑞洛在无基因分型情况下,于急性冠脉综合征和PCI后预防主要不良心血管事件优于氯吡格雷,但均与 increased risk for non-coronary artery bypass-related bleeding 相关。
- 氯吡格雷的药物遗传学数据在PCI情境下最为稳健,其他适应症的证据正在积累。
关键数值与推荐
- 专家共识组和监管机构已提供指导,协助将遗传信息整合入P2Y12抑制剂处方决策。
临床怎么用
- 可利用CYP2C19基因型数据指导PCI术后P2Y12抑制剂治疗选择。
- 选择P2Y12抑制剂时应综合考虑临床和遗传因素,以平衡动脉血栓和出血风险。
局限性
- 本文描述了该领域仍存在的差距。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Oral P2Y12 inhibitors are commonly prescribed for cardiovascular disease and include clopidogrel, prasugrel, and ticagrelor. Each of these drugs has its strengths and weaknesses. Prasugrel and ticagrelor are more potent inhibitors of platelet aggregation and were shown to be superior to clopidogrel in preventing major adverse cardiovascular events after an acute coronary syndrome and percutaneous coronary intervention (PCI) in the absence of genotyping. However, both are associated with an increased risk for non-coronary artery bypass-related bleeding. Clopidogrel is a prodrug requiring bioactivation, primarily via the CYP2C19 enzyme. Approximately 30% of individuals have a CYP2C19 no function allele and decreased or no CYP2C19 enzyme activity. Clopidogrel-treated carriers of a CYP2C19 no function allele have decreased exposure to the clopidogrel active metabolite and lesser inhibition of platelet aggregation, which likely contributed to reduced clopidogrel efficacy in clinical trials. The pharmacogenetic data for clopidogrel are most robust in the setting of PCI, but evidence is accumulating for other indications. Guidance is available from expert consensus groups and regulatory agencies to assist with integrating genetic information into P2Y12 inhibitor prescribing decisions, and CYP2C19 genotype-guided antiplatelet therapy after PCI is one of the most common examples of clinical pharmacogenetic implementation. Herein, we review the evidence for pharmacogenetic associations with clopidogrel response and outcomes with genotype-guided P2Y12 inhibitor selection and describe guidance to assist with pharmacogenetic implementation. We also describe processes for applying genotype data for P2Y12 inhibitor therapy selection and remaining gaps in the field. Ultimately, consideration of both clinical and genetic factors may guide selection of P2Y12 inhibitor therapy that optimally balances the atherothrombotic and bleeding risks.
引用
- Thomas CD, Williams AK, Lee CR, et al. Pharmacogenetics of P2Y12 receptor inhibitors. Pharmacotherapy. 2023. PMID: 36588476. doi:10.1002/phar.2758
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。